IKKβ and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated

Ali Khoshnan1, Adam Sabbaugh1, Barbara Calamini2

  • 1Biology and Bioengineering, California Institute of Technology, Pasadena, CA 91125, USA.

Human Molecular Genetics
|October 4, 2017
PubMed

Insights

Neuronal interleukin-34 (IL-34) drives microglial expansion in Huntington's disease (HD). Blocking IL-34 signaling reduced neurodegeneration, revealing a therapeutic target for HD.

Area of Science:

  • Neuroscience
  • Neuroimmunology
  • Neurodegenerative Diseases

Background:

  • Neuronal interleukin-34 (IL-34) promotes microglial expansion in the central nervous system.
  • Microglial activation and expansion are implicated in Huntington's disease (HD) pathogenesis.

Purpose of the Study:

  • To investigate if mutant huntingtin exon-1 fragment (mHTTx1) accumulation modulates IL-34 expression in neurons.
  • To elucidate the role of IL-34 in mHTTx1-induced neurodegeneration in HD.

Main Methods:

  • Used human embryonic stem cell-derived dopaminergic neurons and a rodent brain slice model.
  • Examined mHTTx1 aggregation, IL-34 production, and neuronal survival under various conditions.
  • Investigated the role of IκB kinase beta (IKKβ) and IL-34 receptor signaling.

Main Results:

  • mHTTx1 aggregates induced IL-34 production in post-mitotic neurons, a response also seen with neuronal stress.
  • IKKβ inhibition prevented mHTTx1 aggregation and IL-34 production.
  • Elevated IL-34 exacerbated mHTTx1-induced neurodegeneration, while IL-34 receptor inhibition ameliorated it.

Conclusions:

  • Novel IKKβ/mHTTx1 interaction regulates IL-34 production.
  • IL-34 plays a critical role in non-cell-autonomous, microglial-dependent neurodegeneration in HD.
  • Targeting IL-34 signaling presents a potential therapeutic strategy for Huntington's disease.